Peptide-decorated liposomes promote arrest and aggregation of activated platelets under flow on vascular injury relevant protein surfaces in vitro.
暂无分享,去创建一个
Timothy L Wong | M. Ravikumar | A. Gupta | Anirban Sen Gupta | Christa L Modery | Madhumitha Ravikumar
[1] J. Levin,et al. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits , 1999, Nature Medicine.
[2] F. Szoka,et al. Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. , 1980, Biochimica et biophysica acta.
[3] Anirban Sen Gupta,et al. Mimicking adhesive functionalities of blood platelets using ligand-decorated liposomes. , 2012, Bioconjugate chemistry.
[4] R. d'Oiron,et al. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[5] M. Blajchman,et al. Novel treatment modalities: new platelet preparations and subsititutes , 2001, British journal of haematology.
[6] T. Fujie,et al. Haemostatic effects of polymerized albumin particles carrying fibrinogen γ‐chain dodecapeptide as platelet substitutes in severely thrombocytopenic rabbits , 2008, Transfusion medicine.
[7] K. Ley,et al. Shear-dependent inhibition of granulocyte adhesion to cultured endothelium by dextran sulfate. , 1989, Blood.
[8] K. Ishihara,et al. Effects of phospholipid adsorption on nonthrombogenicity of polymer with phospholipid polar group. , 1993, Journal of biomedical materials research.
[9] M. Murata,et al. Targeting of liposomes carrying recombinant fragments of platelet membrane glycoprotein Ibalpha to immobilized von Willebrand factor under flow conditions. , 2000, Biochemical and biophysical research communications.
[10] K. Anderson,et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients , 1995, Transfusion.
[11] R. d'Oiron,et al. Recombinant activated factor VII (NovoSeven®) treatment of platelet‐related bleeding disorders , 2000 .
[12] M. Rybak,et al. A liposome based platelet substitute, the plateletsome, with hemostatic efficacy. , 1993, Biomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology.
[13] M. Murata,et al. Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia/IIa and Ib alpha under flow conditions: specific synergy of receptor-ligand interactions. , 2002, Blood.
[14] J. Baldassare,et al. Reconstruction of platelet proteins into phospholipid vesicles. Functional proteoliposomes. , 1985, The Journal of clinical investigation.
[15] M. Misgav,et al. Recombinant activated factor VII (NovoSeven™): addition to replacement therapy in acute, uncontrolled and life‐threatening bleeding , 2004, Vox sanguinis.
[16] P. Rebulla,et al. Platelet transfusions , 2007, The Lancet.
[17] M. Blajchman,et al. Platelet substitutes and novel platelet products , 2000, Expert opinion on investigational drugs.
[18] B. Coller,et al. Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. , 1992, Journal of Clinical Investigation.
[19] T. Fujie,et al. Development of fibrinogen γ‐chain peptide‐coated, adenosine diphosphate‐encapsulated liposomes as a synthetic platelet substitute , 2009, Journal of thrombosis and haemostasis : JTH.
[20] J. May,et al. Interactions of platelets with Synthocytes, a novel platelet substitute. , 2002, Platelets.
[21] M. Penn,et al. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. , 2008, Biomaterials.
[22] D. Mohanty. Current concepts in platelet transfusion , 2009, Asian journal of transfusion science.
[23] Theo H Smit,et al. Dynamic shear stress in parallel-plate flow chambers. , 2005, Journal of biomechanics.
[24] Eishun Tsuchida,et al. Hemostatic effects of polymerized albumin particles bearing rGPIa/IIa in thrombocytopenic mice. , 2003, Biochemical and biophysical research communications.
[25] Y. Teramura,et al. Conjugation of von Willebrand factor-binding domain of platelet glycoprotein Ib alpha to size-controlled albumin microspheres. , 2000, Biomacromolecules.
[26] Paolo Rebulla,et al. Transfusion Medicine 2 Platelet transfusions , 2007 .
[27] Peter Rhee,et al. QuikClot use in trauma for hemorrhage control: case series of 103 documented uses. , 2008, The Journal of trauma.
[28] M. Felfernig,et al. Experience of recombinant activated factor VII (NovoSeven®) in the operating theatre and intensive care unit for the management of intracranial bleeding in nonhaemophilic patients , 2008, Clinical Neurology and Neurosurgery.
[29] U. Hedner. Recombinant factor VIIa (NovoSeven) as a hemostatic agent. , 2001, Disease-a-month : DM.
[30] N. Blumberg,et al. Optimizing platelet transfusion therapy. , 2004, Blood reviews.
[31] Hidenori Suzuki,et al. New strategy of platelet substitutes for enhancing platelet aggregation at high shear rates: cooperative effects of a mixed system of fibrinogen γ-chain dodecapeptide- or glycoprotein Ibα-conjugated latex beads under flow conditions , 2006, Journal of Artificial Organs.
[32] Rebecca Robinson,et al. Intravenous Hemostat: Nanotechnology to Halt Bleeding , 2009, Science Translational Medicine.
[33] K. Robinson. Controlling bleeding in the field: hemostatic powders and dressings debut in the prehospital setting. , 2004, Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association.